We have reported previously on Elmiron-related eye damage, particularly that long-term use of the interstitial cystitis treatment drug Elmiron has been linked to maculopathy eye damage. In this post, we present a 2021 Elmiron medical journal article wherein it is estimated that around 20% of interstitial cystitis patients with long-term Elmiron use may eventually be diagnosed with Elmiron-associated pigmentary maculopathy.
In the March 2021 edition of Current Opinion in Ophthalmology, a medical journal article elaborated on the degree of increased risk of Elmiron-associated pigmentary maculopathy. Here is the Abstract for “Update on maculopathy secondary to pentosan polysulfate toxicity” which provides some important details:
Purpose of review: The aim of the present review is to provide a comprehensive summary of available knowledge regarding toxic maculopathy secondary to [Elmiron, or pentosan polysulfate sodium (PPS)].
Recent findings: [Elmiron (PPS) toxicity] was described in 2018, and additional studies characterize it as dysfunction of the retinal pigment epithelium centered on the posterior pole, which can progress despite drug cessation. Requisite exposure can be as little as 0.325 kg and 2.25 years but averages closer to 1–2 kg and 10–15 years. Multimodal imaging should include near-infrared reflectance, optical coherence tomography, and fundus autofluorescence. Cross-sectional studies demonstrate evidence correlating cumulative dosing and the likelihood/severity of maculopathy. Early estimates of prevalence range from 12.7 to 41.7% depending on dosing, with overall rates around 20%.
It is important to know that a patient does not need to have current Elmiron use right up until the time when their pigmentary maculopathy is diagnosed for it to be considered Elmiron-related eye damage.
We are currently investigating possible Elmiron lawsuits for patients with past Elmiron use diagnosed with pigmentary maculopathy. If we can assist you with an Elmiron-related eye damage legal case, you can submit an online Elmiron Case Evaluation Form or call us on our toll-free number: 800-426-9535.
[Read article in full at original source]